The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting the strong performance of its existing product portfolio, Amgen has upwardly revised its full-year financial guidance. According to reports, the company now expects total revenue to range between $38.2 billion and $39.4 billion, driven by robust drug sales. However, alongside this update, the company announced it is halting the development of a potential obesity treatment that was in phase 1 clinical trials.
This mixed update comes as the healthcare sector undergoes strategic shifts, with the decision to end the obesity program suggesting a reprioritization of Amgen's pipeline. Per market data, AMGN shares closed at $378.87 on August 3, 2026, after reaching a daily high of $391.03 during the session.
Traders should watch for price stability near the recent low of $375.96 (as of August 3, 2026 close). While the current calendar shows no immediate upcoming catalysts for the company, the focus will remain on how the market balances the improved revenue outlook against the disappointment of exiting a high-growth obesity drug category.